We recently reported on CAR T cells recognizing the cancer stem cell (CSC) antigen AC133, an N-glycosylation-dependent, stem cell-specific epitope of CD133, marking CSCs of many tumor entities including the highly malignant glioblastoma multiforme (GBM) [4,5]. The gene discussed is PROM1; the disease is glioblastoma.